Octreotide LAR in Carcinoid
- 1 October 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 37 (3), 337-338
- https://doi.org/10.1097/mpa.0b013e31818adf4b
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid PatientsPancreas, 2008
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeJournal of Clinical Oncology, 1999
- OctreotideThe New England Journal of Medicine, 1996
- Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Mechanisms of action of long-acting analogs of somatostatinRegulatory Peptides, 1993